Opko insists that ‘outliers’ screwed up its big PhIII study on a Pfizer-partnered therapy
Near the beginning of this year, Opko Health shares $OPK took a dive when the company reported out that its Phase III study of a long-acting growth hormone partnered with Pfizer had flopped. But it insisted that “outliers” in the study may have corrupted the results.
Today, Opko is insisting that these unidentified “outliers” are, in fact, the chief culprit for the fail. In a statement this morning, the company reported:
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.